한글목차

거대세포바이러스 치료 시장 규모는 2025년 5억 3,931만 달러에서 2026년부터 2034년까지 CAGR 6.6%로 성장하여 2034년에는 9억 5,864만 달러에 달할 것으로 예측됩니다.

CMV(Cytomegalovirus) 치료 시장은 장기 이식 환자, HIV/AIDS 환자 등 면역결핍 상태의 사람들을 중심으로 CMV 감염 증가 추세에 힘입어 큰 폭의 성장이 예상됩니다. 망막염, 장기 기능 장애 등 CMV와 관련된 장기적인 합병증에 대한 인식이 높아짐에 따라 의료진은 효과적인 치료 전략을 우선순위에 두고 있습니다. 간시클로버, 포스칼넷과 같은 항바이러스 치료제와 더불어 CMV 특이적 경로를 타겟으로 하는 새로운 치료제에 대한 수요가 급증하고 있습니다. 이러한 표적 치료제에 대한 관심이 높아짐에 따라 환자의 치료 결과를 개선하고 CMV 관련 질환의 부담을 줄일 수 있을 것으로 기대됩니다.

의약품 개발의 혁신도 CMV 치료 시장의 미래를 형성하고 있습니다. CMV에 대한 새로운 작용 기전을 제공하는 레테르모빌과 같은 새로운 항바이러스제의 등장으로 임상의가 이용할 수 있는 치료 옵션이 확대되고 있습니다. 또한, 맞춤형 의료의 발전은 유전적 소인과 면역 반응을 포함한 개별 환자 프로필을 기반으로 한 맞춤형 치료 요법의 길을 열어주고 있습니다. CMV의 병태생리의 복잡성이 조사를 통해 계속 밝혀지고 있는 가운데, 항바이러스 효과를 상승시키는 병용요법의 개발이 진행되어 시장의 성장을 더욱 촉진할 것으로 예상됩니다.

또한, 제약회사들이 이 바이러스 감염과 관련된 미충족 수요를 인식함에 따라 연구개발에 대한 투자 증가는 CMV 치료 시장에 긍정적인 영향을 미칠 것입니다. 학계, 산업계, 의료 서비스 제공자 간의 협력은 임상시험을 추진하고 혁신적인 치료법을 시장에 출시하는 데 있어 매우 중요합니다. 이러한 환경 변화에 따라 규제 당국은 새로운 치료법의 승인 절차를 간소화하고, 생명을 구하는 치료법에 대한 신속한 접근을 촉진할 것으로 예상됩니다. 스크리닝 및 조기 발견 방법의 개선에 초점을 맞추는 것도 CMV 감염 관리에서 중요한 역할을 할 것이며, 향후 몇 년 동안 환자 치료 및 치료 결과를 개선하는 데 기여할 것입니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 거대세포바이러스 치료 시장 : 약물 유형별

제5장 세계의 거대세포바이러스 치료 시장 : 용도별

제6장 세계의 거대세포바이러스 치료 시장 : 투여 경로별

제7장 세계의 거대세포바이러스 치료 시장 : 유통 채널별

제8장 세계의 거대세포바이러스 치료 시장 : 지역별

제9장 경쟁 구도

제10장 기업 개요

영문목차

The Cytomegalovirus Treatment Market size is expected to reach USD 958.64 Million in 2034 from USD 539.31 Million (2025) growing at a CAGR of 6.6% during 2026-2034.

The cytomegalovirus (CMV) treatment market is poised for significant growth, driven by the increasing prevalence of CMV infections, particularly among immunocompromised populations such as organ transplant recipients and individuals living with HIV/AIDS. As awareness of the long-term complications associated with CMV, including retinitis and organ dysfunction, continues to rise, healthcare providers are prioritizing effective treatment strategies. The market is witnessing a surge in demand for antiviral therapies, including ganciclovir and foscarnet, as well as emerging therapies that target CMV-specific pathways. This growing focus on targeted treatments is expected to enhance patient outcomes and reduce the burden of CMV-related diseases.

Innovations in drug development are also shaping the future of the CMV treatment market. The advent of novel antiviral agents, such as letermovir, which offers a new mechanism of action against CMV, is expanding the therapeutic options available to clinicians. Additionally, advancements in personalized medicine are paving the way for tailored treatment regimens based on individual patient profiles, including genetic predispositions and immune responses. As research continues to uncover the complexities of CMV pathogenesis, the development of combination therapies that synergistically enhance antiviral efficacy is likely to gain traction, further driving market growth.

Furthermore, the CMV treatment market will benefit from increased investment in research and development, as pharmaceutical companies recognize the unmet medical needs associated with this viral infection. Collaborative efforts between academia, industry, and healthcare providers will be crucial in advancing clinical trials and bringing innovative therapies to market. As the landscape evolves, regulatory bodies are expected to streamline approval processes for new treatments, facilitating faster access to life-saving therapies. The focus on improving screening and early detection methods will also play a vital role in managing CMV infections, ultimately contributing to better patient care and outcomes in the years to come.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Valganciclovir
• Ganciclovir
• Cidofovir
• Foscarnet
• Other

By Applications

• Stem cell transplantation
• Organ transplantation
• Congenital CMV infection
• Other

By Route of Administration

• Oral
• Intravenous

By Distribution Channel

• Hospital pharmacies
• Retail Pharmacies
• E-commerce

COMPANIES PROFILED

• Chimerix, Clinigen Group PLC, F HoffmannLa Roche Ltd, Fresenius Kabi, Genentech Inc, Gilead Sciences Inc, Merck Co Inc, Mylan NV, Pfizer Inc, Takeda Pharmaceuticals

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Valganciclovir Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Ganciclovir Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cidofovir Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Foscarnet Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET: BY APPLICATIONS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Applications
• 5.2. Stem cell transplantation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Organ transplantation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Congenital CMV infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. E-commerce Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Type
  • 8.2.2 By Applications
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Type
  • 8.3.2 By Applications
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Type
  • 8.4.2 By Applications
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Type
  • 8.5.2 By Applications
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Type
  • 8.6.2 By Applications
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CYTOMEGALOVIRUS TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Chimerix
  • 10.2.2 Clinigen Group PLC
  • 10.2.3 F. Hoffmann-La Roche Ltd
  • 10.2.4 Fresenius Kabi
  • 10.2.5 Genentech Inc
  • 10.2.6 Gilead Sciences Inc
  • 10.2.7 Merck & Co. Inc
  • 10.2.8 Mylan N.V
  • 10.2.9 Pfizer Inc
  • 10.2.10 Takeda Pharmaceuticals